Following a £45 million investment, a pharmaceutical factory in Grangemouth will expand.
India-based Piramal Pharma Solutions plans to create up to 50 new jobs by making antibody drugs under contract with other medicine developers.The move will bring the total number of employees at the site to more than 250. Scottish Enterprise, which is backing the expansion with £2.4m, said the investment was "tremendous news" for Scotland's life sciences sector.
Piramal wants the new building at Grangemouth to improve its ability to develop clinical products rapidly, and to support cancer drug trials. In the first phase of the site expansion, two new ADC (Antibody-Drug Conjugate) manufacturing suites will be added to the existing three.
"Piramal's money invested is massive news for Scotland's life sciences sector, one of the broadest life sciences clusters in Europe, and is developing new, high- quality jobs that are essential to our economic growth," said Scottish Enterprise chief executive Adrian Gillespie.
The company's Grangemouth site expansion proposals, with Scottish Enterprise support, will provide more R&D and production capacity for the advancement, scale-up, and commercial manufacture of drugs in the global fight against cancer.
"This new development will more than double our ADC production capacity, enhancing our capability to satisfy clients throughout the entire drug lifecycle," said Piramal Pharma CEO Peter DeYoung.
World BI Group examines how drugs like these could affect drug production and innovation and all the challenges that come along with it. This year's 17th Drug Discovery Innovation Programme will highlight the challenges that discovery pipelines face as a result of COVID-19, as well as put a spotlight on the adoption of technology to find solutions, so if you’re someone interested in the pharmaceutical industry, we encourage you to join the 17th Drug Discovery Innovation Programme 2022, which is a prominent platform for interacting with the world's most influential and dynamic professionals. With the 17th Drug Discovery Innovation Programme 2022, learn how modernization in R&D processes is fundamentally changing what drug discovery research will look like in the next two to five years. So, join us in October 2022 for an in-person experience and two days of top-level strategic content and current scientific insights, networking, and discussions with top global pharmaceutical R&D executives. This event will give you a chance to join and get a complete learning experience about the challenges and their solutions from experts in the field. Register Here to meet new clients, build your brand, get a handle on the market and drive new business.